

REMARKS

Restriction to one of the following Groups was required under 35 U.S.C. 121 and 372:

Group I: Claims 1-28, drawn to a nucleic acid molecule.

Group II: Claims 29-38, drawn to an isolated protein.

Group III: Claims 39-40, drawn to a method of modulating DEC-205 expression or functional activity.

Group IV: Claims 41-43, drawn to a method for regulating cellular activity.

Group V: Claims 44-45, drawn to a method for treatment and/or prophylaxis of a condition characterized by aberrant, unwanted, or inappropriate functioning of DEC-205 SV.

Group VI: Claim 50, drawn to a pharmaceutical composition.

Group VII: Claims 51 and 53, drawn to an antibody directed to a protein.

Group VIII: Claims 52 and 54, drawn to an antibody directed to a nucleic acid molecule.

Group IX: Claim 55, drawn to a method of diagnosis.

Group X: claim 56, drawn to a method for detecting an agent capable of modulating the function of DEC-205 SV or DCL-1.

Response to Restriction Requirement

In response to the Restriction Requirement, Applicants elect Group II encompassing Claims 29-38, drawn to an isolated protein.

Request for Rejoinder

Upon allowance of Group II claims, Applicants respectfully request rejoinder of withdrawn Claim 50 which has been amended to be ultimately dependent on the elected Group II claims and include all of the limitations of Claim 29.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, the Applicants are not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. The Applicants reserve the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior

prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that the Applicants have made any disclaimers or disavowals of any subject matter supported by the present application.

Co-Pending Applications of Assignee

Applicant wishes to draw the Examiner's attention to the following co-pending applications of the present application's assignee.

Serial Number	Title	Filed
10/536,677	THERAPEUTIC AND DIAGNOSTIC AGENTS	June 5, 2006
11/888,911	DCL-1 AND USES THEREOF	July 31, 2007
10/538,393	IN VITRO IMMUNIZATION	November 13, 2006

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 30, 2007

By: _____

Raymond D. Smith
Registration No. 55,634
Agent of Record
Customer No. 20995
(805) 547-5580